Future of Type 1 Diabetes Treatment
Beta?
“B.E.T.A.”
Active Islet Encapsulation, The Next-Generation Islet Transplantation
The Missing Piece in Diabetes Care
While insulin therapy manages the symptoms of Type 1 Diabetes, it is not a cure. Even promising cellular transplants fail due to a "double threat": immune rejection from the outside and toxic amyloid buildup from the inside. At BIOETA, we have engineered the first system designed to stop both. Discover how our B.E.T.A. System uses active amyloid-trapping technology to protect transplanted cells and offer a drug-free, long-term solution.
What is “B.E.T.A.”?
Bio-engineered Encapsulation for Therapeutic Amyloid-protection
The world's first bioactive immunoisolation technology featuring a genetically engineered recombinant enzyme.
Who We Are
BIOETA is a pioneering biotechnology company dedicated to solving the challenge in regenerative medicine. We are moving beyond the era of insulin injections by engineering the first "active" cell encapsulation system—one that protects transplanted cells from both immune rejection and their own metabolic waste. At BIOETA, we aren't just managing Diabetes, we are engineering its cure.
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!